Friday 7 June 2019

Bone Scan Market Pipeline Review, 2019- Identify Key Business Opportunities

According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.
The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.
bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.
Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.
Key Players in the Global Bone Scan Market   
  • Siemens (U.S.)
  • Hitachi, Ltd. (Japan)
  • Carestream Health, Inc. (U.S.)
  • Samsung Electronics Co., Ltd. (South Korea)
  • Toshiba Corporation. (Japan)
  • Koninklijke Philips N.V. (Netherlands)
  • General Electric Company (U.S.)
Segments of the Global Bone Scan Market
The global bone scan market is segmented on the basis of product, indication, device, and end user.
On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.
On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis
The Americas lead the global bone scan market owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.
Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.
The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bone-scan-market-5027

TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
…TOC Continued!

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Thursday 6 June 2019

Biochips Market Research Report 2019 Analysis and Forecast to 2023

Market Scenario:
Global Biochips Market held a market value of USD 7,300 million in 2017, according to the latest research report from Market Research Future (MRFR). The market is expected to exhibit a strong 16.6% CAGR over the forecast period from 2018 to 2023, according to the report.
Biochips are intended to function in biological environment, preferably inside living organism. The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications of biochips will boost the market growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.  
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7063            
However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.
According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Competitive Landscape:Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.
Segmentation:The Global Biochips Market has been segmented into type, technology, and end user.
By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.
Based on technology, the market has been segmented into microarrays and microfluidics.
The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region.  
The Middle East & Africa has the lowest share of the global biochips market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.  
         

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Animal Genetics Market Growth and Restrain Factors Analysis By 2023

Market Scenario:
Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers.
The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.
The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.

Key players:
  • Neogen Corporation (US),
  • Genus (UK),
  • URUS (US),
  • EW Group (Germany),
  • Groupe Grimaud (France),
  • CRV Holding B.V. (The Netherland),
  • Topigs Norsvin (Netherlands),
  • Zoetis (US),
  • Envigo (US)
  • Hendrix Genetics BV (The Netherland),
  • Animal Genetics (US),
  • Alta Genetics (US),
  • vetGen (US)
Segmentation:The Global Animal Genetics Market is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others
Regional Market Summary 
The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.
The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.
The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

 


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Genetic Testing Market - Granular Market Report and Review, 2019

Market Scenario:
The Global Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024. Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.
Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.
Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.
Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.
Key Players
The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.
  • In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
  • In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
  • In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.
Segmentation                                                                                                                                        
Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Regional Analysis         
The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.
Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.
Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Precision Medicine Market - Granular Market Report and Review, 2019

Market Scenario:
Market Research Future adds the “Global Precision Medicine Market Research Report – Forecast to 2022” report to their unique collection. The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
Precision medicine refers to medicines developed as per an individual’s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases. The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2022.
The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
Key Findings:
  • The global precision medicine market is expected to reach USD 88.64 billion by 2022.
  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2022.
  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2022.
Segmentation:
Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.
Regional Analysis
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Tuesday 4 June 2019

Nasal Drug Delivery Market to Observe Significant Growth by 2019

Market Scenario
The intra-nasal route of drug administration is becoming popular due to its noninvasive nature thereby reducing pain and threat of infections and allows the patient to self-administer drugs without any help from anyone. Moreover recent research has also pointed its applications related to drug delivery to the brain. Bioavailability of a drug is defined as the proportion of a drug entering the systemic circulation as compared to the dosage. Nasal drug delivery eliminates drug destruction by HCL present in the stomach thereby increasing bioavailability which reduces the dosage of the drug. The reduction in dosage leads to proportional reduction in side effects. Growth of over the counter nasal drugs such as inhalers for common cold is also driving the market.
The market for nasal drug delivery is increasing at a good CAGR due to the above mentioned advantages of nasal drugs.  Other market driving factors include ease of administration, growing efficacy of the route due to development of drugs which are absorbed easily from the nasal route and the development of advanced products such as metered dose pressurized containers which deliver a very precise dose.
The market’s constraints are irritation of the nasal route and the low dose of the drug that can be delivered as compared to other route of administration. Other constraints includes low awareness and concurrent low popularity of the route which reduces economies of scale in producing these delivery devices. The market for nasal drug delivery has oligopolistic characteristic due to a few dominant players. Thus the power of the sellers is high and there is a premium on most nasal drug delivery products.
Taking all factors into consideration, we expect the Middle East and Africa nasal drug delivery market to reach around $ 1.59 billion in 2022 growing at a CAGR of 8.1%; this market was worth $ 1 billion in 2015.
Key Players
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi-Aventis
  • Merck & Co., Inc.
  • AptarGroup Inc.
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline plc
  • Becton Dickson & Company
Segments:
Middle East and Africa nasal drug delivery market has been segmented on the basis of dosage form which comprises of drops, sprays, powder, gels and ointments. On the basis of system, market is segmented into unit dose, multi-dose and metered dose. On the basis of delivery technologies; market is segmented into spray, nebulizers and other. On the basis of therapeutic applications; market is segmented into rhinitis, congestion, vaccinations and others.
Regional Analysis
UAE is the largest market for nasal drug delivery in entire Middle East and Africa nasal drug delivery Market closely followed by Egypt. The rest of Africa’s market is growing at a very fast rate due to huge unmet medical needs and growing popularity of nasal route.
Drivers and Restraints
The market for nasal drug delivery is growing remarkably with a consistently good CAGR due to the benefits accompanying nasal drugs.  Other driving factors include innovation of drugs which are absorbed easily from the nasal route, innovations in advanced products which allow the delivery of precise doses and also ease of administration. However, the restraints that threaten the growth of the market are irritation of the nasal route and the low dose of the drug that can be delivered as compared to other routes of administration. Other constraints include concurrent low popularity of the route which reduces economies of scale in producing these delivery devices and low awareness. According to an extensive report by Market Research Future (MRFR), the Middle East and Africa nasal drug delivery market is presumed to reach around USD 1.59 billion in 2022 surging at a CAGR of 8.1% from 2017 to 2022. The market was estimated to be worth USD 1 billion in 2015.
Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696
          
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Dyspepsia Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Dyspepsia is a chronic medical condition which causes discomfort in the upper abdomen as a result of indigestion. The stomach and the small intestine, and sometimes the esophagus does not function properly which is the main reason for the discomfort. Gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine are other causes for dyspepsia. Overeating, over-consumption of alcohol and smoking, might also cause dyspepsia. The global dyspepsia market is perceived to be a steadily growing market as per the analysis of market Research Future (MRFR).
Surging prevalence of digestive diseases across the globe is one of the prime reasons for the growth of the global dyspepsia market. The Centers for Disease Control and Prevention estimated 14.7 Mn people in the US to be suffering from digestive ulcers in 2016. Also, the American Cancer Society projected 26,240 new cases of stomach cancer to be diagnosed in the year 2018. The rise in the global geriatric population remains a significant growth driver. The aged populace is generally more susceptible to digestive disorders and induces high demand for diagnosis & treatment. Other factors boosting the growth of the market include the growing occurrence of diabetes and thyroid among the global population. Rigorous R&D activities to develop new drugs and therapies are also likely to augur the growth of the market over the forecast period. Unhealthy diet and a sedentary lifestyle can also be considered as a major reason for the growth of the global dyspepsia market. Due to the current busy lifestyle, consumers are more prone to consuming on-the-go food items which are generally unhealthy and cause digestive disorders. Additionally, such a situation is worsened by smoking and alcohol consumption which favors market growth. On the flipside, the growth of the market might be hindered by high costs associated with diagnostic tests and cut-throat competition among market players.
Competitive Landscape
The notable players in the global dyspepsia market are
  • Allergan Plc,
  • Takeda Pharmaceutical Company,
  • Abbott Laboratories,
  • Johnson & Johnson,
  • Eisai Co., Ltd.,
  • Sanofi,
  • Bayer AG,
  • Salix Pharmaceuticals,
  • AstraZeneca,
  • Boehringer Ingelheim GmbH,
Segmentation
The global dyspepsia market has been segmented based on diagnosis, treatment, and end user.
By diagnosis, the global dyspepsia market has been segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others.
By treatment, the global dyspepsia market has been segmented into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies, and others. The antacids segment has been further segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate, and others. The antibiotic segment has been further segmented into amoxicillin, clarithromycin, metronidazole, and others.  The H2 blockers segment has been further segmented into cimetidine, famotidine, nizatidine, ranitidine, and others. The Proton pump inhibitors (PPIs) segment has been further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide.
By end user, the global dyspepsia market has been segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers, and others.
Regional Analysis
By region, the global dyspepsia market has been segmented into the Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA).
Browse Complete 100 Pages Premium Research Report Enabled with 80 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dyspepsia-market-6351
       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com